Drugs for Oral Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 116)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Nicotine |
Approved |
Phase 4 |
|
54-11-5 |
942 89594 |
Synonyms:
(−
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-methylpyrrolidino)Pyridine
(−)-nicotine
(-)-Nicotine
(-)-Nicotine solution
(+)-Nicotine
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(S)-(−)-nicotine
(S)-(-)-Nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(1-Methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-Methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridal)-pyrrolidine
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(2-(N-Methylpyrrolidinyl))pyridine
3-(N-methylpyrollidino)pyridine
3-(N-methylpyrollidino)Pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-methylpyrrolidino)Pyridine
3-(N-Methylpyrrolidino)pyridine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
3-N-Methylpyrrolidine
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
a -N-Methylpyrrolidine
AC1L3I79
AC1Q3ZOC
AI3-03424
alpha-N-Methylpyrrolidine
a-N-Methylpyrrolidine
BB_NC-0777
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
BIDD:GT0599
Bitartrate, nicotine
Black Leaf
Black Leaf 40
bmse000105
BRD-K05395900-322-02-1
C00745
Campbell's Nico-Soap
Caswell No. 597
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
Commit
CPD000059074
D03365
delta-Nicotine
Destruxol
Destruxol Orchid Spray
DL-Tetrahydronicotyrine
D-Nicotine
EINECS 200-193-3
Emo-Nik
ENT 3,424
EPA Pesticide Chemical Code 056702
Flux Maag
fumeto Bac
Fumetobac
|
Habitrol
Habitrol (TN)
HSDB 1107
L(-)-nicotine
L(−)-nicotine
L(-)-Nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
L-Nicotine
LS-202
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MLS001055457
MLS001335905
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
Niagara P.A. Dust
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nico-Dust
Nico-Fume
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
nicotine
Nicotine
Nicotine (compounds related to)
Nicotine (USP)
Nicotine [BSI:ISO]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotine Alkaloid
NICOTINE AND SALTS
Nicotine betadex
Nicotine bitartrate
Nicotine Patch
Nicotine polacrilex
Nicotine Polacrilex
nicotine replacement patch
Nicotine tartrate
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nic-Sal
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
NSC 5065
NSC97238
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tartrate, nicotine
Tendust
Transdermal Nicotine
UN1654
|
|
2 |
|
Dopamine |
Approved |
Phase 4 |
|
51-61-6, 62-31-7 |
681 |
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
3 |
|
Bupropion |
Approved |
Phase 4 |
|
34911-55-2, 34841-39-9 |
444 |
Synonyms:
( -)-2-(tert-Butylamino)-3'-chloropropiophenone
( -)-2-(tert-Butylamino)-3'-chlorpropiophenon
(+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone
(+-)-1-(3-Chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone
(+-)-Bupropion
.alpha.-(tert-Butylamino)-m-chloropropiophenone
1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
2-(Tert-Butylamino)-3'-chloropropiophenone
34841-36-6 (hydrochloride)
34841-39-9
34911-55-2
AB00053756
AC-197
AC1L198Y
alpha-(tert-butylamino)-m-chloropropiophenone
Amfebutamon
Amfebutamona
Amfebutamona [INN-Spanish]
Amfebutamone
AMFEBUTAMONE HCl
amfebutamonum
Amfebutamonum
Amfebutamonum [INN-Latin]
BPBio1_000042
BRD-A05186015-003-05-7
BRN 2101062
BSPBio_000038
BSPBio_002247
bupropion
Bupropion
Bupropion (INN)
Bupropion (Old RN)
Bupropion (USAN)
Bupropion [INN:BAN]
Bupropion Hcl
Bupropion hydrochloride
Bupropion hydrochloride, (+-)-isomer
Bupropion hydrocloride
Bupropion SR
Bupropion, (+-)-isomer
C06860
CHEBI:3219
CHEMBL894
CID444
CPD000472526
D07591
DB01156
DivK1c_007050
Elont
|
Esteve brand OF bupropion hydrochloride
glaxo Wellcome brand 1 OF bupropion hydrochloride
glaxo Wellcome brand 2 OF bupropion hydrochloride
glaxo Wellcome brand 3 OF bupropion hydrochloride
GlaxoSmithKline brand 1 OF bupropion hydrochloride
GlaxoSmithKline brand 2 OF bupropion hydrochloride
HMS2051G10
HMS2089G14
Jsp006301
KBio1_001994
KBio2_002143
KBio2_004711
KBio2_007279
KBio3_001467
KBioGR_001168
KBioSS_002143
L000725
Lopac0_000166
LS-122817
MLS001424015
MolPort-003-845-432
NCGC00015122-06
NCGC00089751-02
NCI60_002714
NSC315851
Prestwick0_000249
Prestwick1_000249
Prestwick2_000249
Prestwick3_000249
Quomen
SAM001246699
SMR000472526
SPBio_001817
SPBio_002257
SpecPlus_000954
Spectrum_001663
Spectrum2_001659
Spectrum3_000644
Spectrum4_000614
Spectrum5_001406
TL8002604
UNII-01ZG3TPX31
Wellbatrin
Wellbutrin
Wellbutrin SR
Wellbutrin XL
Zyban
Zyban (anti-smoking)
Zyntabac
|
|
4 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
5 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
6 |
|
Liver Extracts |
|
Phase 4 |
|
|
|
7 |
|
Central Nervous System Stimulants |
|
Phase 4 |
|
|
|
8 |
|
Cholinergic Agents |
|
Phase 4 |
|
|
|
9 |
|
Nicotinic Agonists |
|
Phase 4 |
|
|
|
10 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 4 |
|
|
|
11 |
|
Dopamine Agents |
|
Phase 4 |
|
|
|
12 |
|
Antidepressive Agents |
|
Phase 4 |
|
|
|
13 |
|
Pilocarpine |
Approved, Investigational |
Phase 2, Phase 3 |
|
54-71-7, 92-13-7 |
5910 |
Synonyms:
(+)-Pilocarpine
(3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one
(3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
(3S,4R)-3-ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone
(3S,4R)-3-ethyldihydro-4-((1-Methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone
(3S-cis)-3-Ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone
(3S-cis)-3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone
(3S-cis)-3-ethyldihydro-4-[(1-Methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone
3-ethyl-4-((1-methyl-1H-imidazol-5-yl)methyl)dihydro-2(3H)-furanone
3-Ethyl-4-(3-methyl-3H-imidazol-4-ylmethyl)dihydrofuran-2-one
3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydro-2(3H)-furanone
3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one
3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
54-71-7
91484-73-0
92-13-7
AC1L1J0W
AC1L1LEF
AC1Q6MOP
Adsorbocarpine
AI3-50523
Almocarpine
Amistura P
AR-1F3128
beta-Pilocarpine hydrochloride
BIDD:GT0217
BPBio1_000548
BRD-K85090592-008-05-2
BSPBio_000498
BSPBio_002191
C07474
CHEBI:39460
CHEBI:8207
CHEMBL550
CID4819
CID5910
D00525
DB01085
DivK1c_000358
EINECS 202-128-4
Epicar
HMS2089K17
HSDB 3163
Hydrochloride, pilocarpine
IDI1_000358
Imidazole-5-butyric acid, alpha-ethyl-beta-(hydroxymethyl)-1-methyl-, gamma-lactone
isopilocarpine
Isopilocarpine
Isopto carpine
Isoptocarpine
KBio1_000358
KBio2_001587
KBio2_004155
KBio2_006723
KBio3_001691
KBioGR_000956
KBioSS_001587
L001181
Lopac0_000950
Lopac0_000960
LS-187208
LS-7661
Minims Pilocarpine
Miocarpine
Mi-Pilo
MolPort-002-512-506
NCGC00023339-03
NCGC00023339-06
|
NCGC00023339-07
NCGC00023339-08
NCGC00023339-09
NCGC00023339-12
NCGC00023339-13
nchembio.78-comp9
NCI60_004403
NINDS_000358
Nitrate, pilocarpine
NSC5746
Ocu-Carpine
Ocusert
Ocusert P 20
Ocusert pilo
Ocusert pilo-20
Ocusert pilo-20 (TN)
Ocusert Pilo-40
P.V. Carpine Liquifilm
Pilagan
Pilocarpin
Pilocarpina
pilocarpine
Pilocarpine
Pilocarpine (JAN/USP)
Pilocarpine [USAN:BAN:JAN]
Pilocarpine chloride
Pilocarpine HCl
Pilocarpine HCL
Pilocarpine hydrochloride
Pilocarpine monohydrochloride
Pilocarpine mononitrate, (3S-cis)-isomer
Pilocarpine Mononitrate, (3S-cis)-Isomer
Pilocarpine muriate
Pilocarpine nitrate
Pilocarpine, monohydrochloride, (3S-cis)-isomer
Pilocarpine, Monohydrochloride, (3S-cis)-Isomer
Pilocarpol
Pilokarpin
Pilokarpin monohydrochloride
Pilokarpol
Piloptic-1
Piloptic-1/2
Piloptic-2
Piloptic-3
Piloptic-4
Piloptic-6
Pilostat
Prestwick0_000449
Prestwick1_000449
Prestwick2_000449
Prestwick3_000449
Salagen
SDCCGMLS-0003164.P005
SPBio_001287
SPBio_002437
Spectrum_001107
Spectrum2_001284
Spectrum3_000546
Spectrum4_000478
Spectrum5_001379
Spersacarpine
Spersacarpine hydrochloride
STOCK1N-18408
Syncarpine
Tocris-0694
UNII-01MI4Q9DI3
ZINC00075008
|
|
14 |
|
Celecoxib |
Approved, Investigational |
Phase 2, Phase 3 |
|
169590-42-5 |
2662 |
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC1L1E6K
AC-4228
AI-525
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
celecoxib
Celecoxib
Célécoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
cMAP_000027
CPD000550473
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
|
KBio2_000912
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
Medicoxib
MLS001165684
MLS001195656
MLS001304708
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulphonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC58635
SC-58635
SMR000550473
Solexa
SPBio_001512
Spectrum_000432
SPECTRUM1503678
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM177
YM-177
ZINC02570895
|
|
15 |
|
Dexamethasone acetate |
Approved, Investigational, Vet_approved |
Phase 2, Phase 3 |
|
1177-87-3 |
|
Synonyms:
16alpha-Methyl-9alpha-fluoroprednisolone 21-acetate
9alpha-Fluoro-16alpha-methylprednisolone acetate
Dexamethasone 21-acetate
|
Dexamethasone acetate anhydrous
Dexamethasone acetate, anhydrous
Dexamethasoni acetas
|
|
16 |
|
Dexamethasone |
Approved, Investigational, Vet_approved |
Phase 2, Phase 3 |
|
50-02-2 |
5743 |
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
137098-19-2
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16a-Methyl-9a-fluoro-1-dehydrocortisol
16α-methyl-9α-fluoro-1-dehydrocortisol
16α-Methyl-9α-fluoro-1-dehydrocortisol
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-dehydro-16alpha -Methyl-9alpha -fluorohydrocortisone
1-dehydro-16alpha-Methyl-9alpha-fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-dehydro-16a-Methyl-9a-fluorohydrocortisone
1-dehydro-16α-methyl-9α-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9a-fluoro-16a-Methylprednisolone
9a-fluoro-16BETA-METHYLPREDNISOLONE
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -fluoro-16alpha -Methylprednisolone
9alpha-fluoro-16alpha-Methylprednisolone
9alpha-fluoro-16alpha-Methyl-prednisolone
9-alpha-fluoro-16-alpha-Methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9-fluoro-11,17,21-Trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-fluoro-11alpha -Methylpregna-1,4-diene-3,20-dione
9-fluoro-16-Methylprednisolone
9α-fluoro-16α-methylprednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
Adexone
Aeroseb-D
Aeroseb-dex
Aeroseb-Dex
AI3-50934
Ak dex OPH otic soln 0.1%
Alcon brand OF dexamethasone
Alcon Brand of Dexamethasone
alpha -fluoro-16-alpha -Methylcortisol
Anaflogistico
Aphtasolon
Aphthasolone
apo-Dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (veterinary)
Azium (Veterinary)
BIDD:ER0494
BIDD:PXR0060
Bisu Ds
Bisu DS
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
C15643
C22H29FO5
Calonat
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
Corson
Corsone
Cortisumman
CPD001227192
CPD-10549
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-La
Decadron-LA
Decagel
Decaject
Decaject l.a.
Decaject L.A.
Decaject-l.a.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
Delta1-9alpha-fluoro-16alpha-Methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [Dcit]
Desametasone [DCIT]
Desamethasone
Desameton
Deseronil
DEX
Dexa
DEXA
Dexa mamallet
Dexa Mamallet
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexa-cortidelt
Dexa-Cortidelt
Dexacortin
Dexa-cortisyl
Dexa-Cortisyl
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexa-Mamallet
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
dexamethasone
Dexamethasone
Dexaméthasone
Dexamethasone (JP15/USP/INN)
|
Dexamethasone [INN:BAN:JAN]
Dexamethasone acetate
Dexamethasone Acetate
Dexamethasone alcohol
Dexamethasone Alcohol
Dexamethasone base
Dexamethasone Base
Dexamethasone intensol
Dexamethasone Intensol
Dexamethasone sodium phosphate
Dexamethasone Sodium Phosphate
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexa-scheroson
Dexa-Scheroson
Dexa-sine
Dexa-Sine
Dexason
Dexasone
Dexasone 0.5MG
Dexasone 0.75MG
Dexasone 4MG
Dexasporin
Dex-ide
Dex-Ide
Dexinolon
Dexinoral
Dexone
Dexone 0.5
DEXONE 0.5
Dexone 0.75
DEXONE 0.75
Dexone 1.5
DEXONE 1.5
Dexone 4
DEXONE 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
DXM
Dxms
DXMS
ECR brand OF dexamethasone
ECR Brand of Dexamethasone
EINECS 200-003-9
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy brand OF dexamethasone
Foy Brand of Dexamethasone
FT-0080377
Gammacorten
Hexadecadrol
Hexadrol
Hexadrol elixir
Hexadrol Elixir
Hexadrol Tablets
Hl-dex
Hl-Dex
HL-Dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
I06-1196
ICN brand OF dexamethasone
ICN Brand of Dexamethasone
IontoDex
isopto-Dex
Isopto-Dex
Lokalison F
Loverine
LS-7300
Luxazone
Maxidex
Maxidex ont 0.1%
Maxidex sus 0.1%
Maxitrol
Mediamethasone
Merck brand OF dexamethasone
Merck Brand of Dexamethasone
Merz brand 1 OF dexamethasone
Merz Brand 1 of Dexamethasone
Merz brand 2 OF dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MK 125
MLS001055412
MLS001332507
MLS001332508
MolMap_000018
MolPort-003-846-433
Mymethasone
Naquasone (veterinary)
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
nchembio809-comp2
NCI60_003067
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
NSC 34521
NSC34521
Ocu-trol
Ocu-Trol
Oradexon
OTO-104
Pet derm III
Pet Derm Iii
Pet Derm III
Pet-Derm Iii
PHL-Dexamethasone
PMS Dexamethasone elixir 0.5mg/5ML
PMS-Dexamethasone
Policort
Posurdex
Prednisolon F
Prednisolone F
Prodex
S1322_Selleck
SAM002548948
Sandoz dexamethasone
SGCUT00126
Sk-Dexamethasone
SK-Dexamethasone
SMP1_000092
SMR000857119
SMR001227192
Spectrum5_002019
Spoloven
ST50307091
Sunia sol D
Sunia Sol D
Superprednol
TL8003317
to_000038
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
|
|
17 |
|
Muscarinic Agonists |
|
Phase 2, Phase 3 |
|
|
|
18 |
|
Gastrointestinal Agents |
|
Phase 2, Phase 3 |
|
|
|
19 |
|
Analgesics, Non-Narcotic |
|
Phase 2, Phase 3 |
|
|
|
20 |
|
Cyclooxygenase Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
21 |
|
Analgesics |
|
Phase 2, Phase 3 |
|
|
|
22 |
|
Anti-Inflammatory Agents |
|
Phase 2, Phase 3 |
|
|
|
23 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 2, Phase 3 |
|
|
|
24 |
|
Angiogenesis Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
25 |
|
Hormones |
|
Phase 2, Phase 3 |
|
|
|
26 |
|
Antineoplastic Agents, Hormonal |
|
Phase 2, Phase 3 |
|
|
|
27 |
|
Cyclooxygenase 2 Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
28 |
|
Anti-Infective Agents |
|
Phase 2, Phase 3 |
|
|
|
29 |
|
Antiemetics |
|
Phase 2, Phase 3 |
|
|
|
30 |
|
Hormone Antagonists |
|
Phase 2, Phase 3 |
|
|
|
31 |
|
Anti-Bacterial Agents |
|
Phase 2, Phase 3 |
|
|
|
32 |
|
glucocorticoids |
|
Phase 2, Phase 3 |
|
|
|
33 |
|
Omeprazole |
Approved, Investigational, Vet_approved |
Phase 2 |
|
73590-58-6 |
4594 |
Synonyms:
( -)-Omeprazole
(-)-Omeprazole
(S)-(-)-Omeprazole
(S)-Omeprazole
119141-89-8
131959-78-9
172964-80-6
2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole
2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole
2,3,5-Trimethylpyridine/Omeprazole
5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole
5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
73590-58-6
AC1L1IIJ
AC-401
AGI-010
AKOS005066653
Antra
Antra mups
Antra MUPS
Audazol
Aulcer
AULCER
Axagon
Belmazol
BIDD:GT0189
Bio-0888
BPBio1_000425
BRD-A55962179-001-04-9
BSPBio_000385
C07324
CAS-73590-58-6
CCRIS 7099
Ceprandal
CHEBI:519601
CHEBI:7772
CHEMBL1503
CID4594
CPD000058847
D00455
Danlox
DB00338
DB00736
Demeprazol
Desec
Dizprazol
DM-3458
Dudencer
Elgam
Emeproton
Emilok
Epirazole
Erbolin
esomeprazol
Esomeprazole
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168/68
H 168-68
H168/68
H-168/68
HMS1528I05
HMS1569D07
HMS2052G17
HMS2090E16
HMS2090F11
HSDB 3575
I06-0705
IDI1_032523
Indurgan
Inhibitron
Inhipump
Lensor
Logastric
Lomac
Losec
Losec, Omesec, Prilosec, Zegerid, Omeprazole
LS-7629
Lucen
Magnesium, omeprazole
Maybridge4_002645
Mepral
Miol
Miracid
MLS000069373
MLS001076112
MLS001424148
MolPort-003-666-741
MolPort-003-807-515
MolPort-003-849-702
Mopral
Morecon
NCGC00016925-01
NCGC00016925-02
|
NCGC00021522-03
NCGC00021522-04
NCGC00021522-05
Nexiam
Nexium
Nexium IV
Nilsec
Nopramin
Nuclosina
O0359
O104_SIGMA
Ocid
Olexin
Olit
Omapren
Omebeta
Omebeta 20
Omed
Omegast
OMEP
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
omeprazole
Omeprazole
Omeprazole (JAN/USP/INN)
Omeprazole [USAN:INN:BAN:JAN]
Omeprazole delayed-release
Omeprazole magnesium
Omeprazole pellets
Omeprazole sodium
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprazone
Omeprol
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
OMP
Ompanyt
OMZ
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Prazentol
Prazidec
Prazolit
Prestwick_808
Prestwick0_000493
Prestwick1_000493
Prestwick2_000493
Prestwick3_000493
Prilosec
Prilosec (TN)
Prilosec otc
Prilosec OTC
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
S1389_Selleck
SAM001246900
SAN-15
Sanamidol
Secrepina
SMR000058847
Sodium, omeprazole
SPBio_002306
STK623746
Tedec ulceral
Tedec Ulceral
TL8005099
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
UNII-KG60484QX9
UPCMLD-DP075
UPCMLD-DP075:001
Victrix
Zefxon
Zegerid
Zepral
Zimor
Zoltum
|
|
34 |
|
Indomethacin |
Approved, Investigational |
Phase 2 |
|
53-86-1 |
3715 |
Synonyms:
{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetate
{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid
1-(P-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetate
1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid
1-(P-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid
1z9h
37242-43-6
503560-73-4
53-86-1
74252-25-8 (hydrochloride salt, tri-hydrate)
7681-54-1 (hydrochloride salt)
91853-74-6
AB00052022
AC1L1GJQ
AC-532
Aconip
Aconip (TN)
AKOS000592893
Amuno
Apo-Indomethacin
Argun
Arthrexin
Artracin
Artrinovo
Artrivia
BIDD:GT0132
BIM-0050670.0001
Bio-0704
Bio2_000405
Bio2_000885
Bonidin
Bonidon
Bonidon Gel
BPBio1_000160
BRD-K57222227-001-06-1
BRN 0497341
BSPBio_000144
BSPBio_001149
BSPBio_002176
C01926
CAS-53-86-1
Catlep
CCRIS 3502
CHEBI:49662
CHEMBL6
Chibro-amuno
Chibro-Amuno
Chrono-indicid
Chrono-Indicid
Chrono-indocid
Chrono-Indocid
CID3715
Confortid
CPD-10545
D00141
DB00328
DESMETHYL INDOMETHACIN
DivK1c_000271
Dolcidium
Dolcidium Pl
Dolcidium PL
Dolovin
Durametacin
EINECS 200-186-5
Elmetacin
EU-0100692
Flexin continus
Flexin Continus
Hicin
HMS1362I11
HMS1568H06
HMS1792I11
HMS1920F21
HMS1990I11
HMS2089N19
HMS2091N09
HMS500N13
HSDB 3101
Hydrochloride, indomethacin
I 7378
I0655
I7378_SIGMA
I8280_SIGMA
IDI1_000271
IDI1_002160
Idomethine
Imbrilon
IMN
IN1454
Inacid
Indacin
Indaflex
Indameth
Indmethacine
Indocid
Indocid (pharmaceutical)
Indocid Pda
Indocid Sr
Indocin
Indocin (TN)
Indocin I.V
Indocin I.V.
Indocin Sr
Indolar Sr
Indolar SR
Indo-Lemmon
Indomecol
Indomed
Indomee
Indomet 140
indometacin
Indometacin
Indometacin (JP15/INN)
Indometacina
Indometacina [INN-Spanish]
Indometacine
Indometacine [INN-French]
Indometacinum
Indometacinum [INN-Latin]
Indometacyna
|
Indometacyna [Polish]
indomethacin
Indomethacin
Indomethacin & MAP-30
Indomethacin (USP)
Indomethacin [USAN:BAN]
Indomethacin hydrochloride
Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin
Indomethacine
Indomethacinum
Indomethancin
Indomethazine
Indomethegan
Indomethine
Indometicina
Indometicina [Spanish]
Indomo
Indomod
Indo-phlogont
Indo-Phlogont
Indoptic
Indoptol
Indo-rectolmin
Indo-Rectolmin
Indorektal
Indo-Spray
Indo-tablinen
Indo-Tablinen
Indoxen
Inflazon
Infrocin
Inteban sp
Inteban Sp
KBio1_000271
KBio2_000489
KBio2_001399
KBio2_003057
KBio2_003967
KBio2_005625
KBio2_006535
KBio3_000897
KBio3_000898
KBio3_001396
KBioGR_000395
KBioGR_000489
KBioSS_000489
KBioSS_001399
L000959
Lausit
Liometacen
Lopac0_000692
Lopac-I-7378
LS-187
LS-82147
Metacen
Metartril
Methazine
Metindol
Mezolin
Miametan
Mikametan
MLS000069402
MLS000758212
MLS001074194
Mobilan
MolMap_000032
MolPort-000-917-894
NCGC00015562-01
NCGC00015562-02
NCGC00015562-03
NCGC00015562-08
NCGC00015562-19
NCGC00024135-02
NCGC00024135-04
NCGC00024135-05
NCGC00024135-06
NCGC00024135-07
NCGC00024135-08
NCGC00024135-09
NCGC00024135-11
nchembio.147-comp11
NCI60_041708
NCI-C56144
NINDS_000271
Novomethacin
Novo-Methacin
Nu-Indo
Oprea1_686105
Osmosin
Prestwick_597
Prestwick0_000272
Prestwick1_000272
Prestwick2_000272
Prestwick3_000272
Reumacide
Rhemacin La
Rhemacin LA
Rheumacin La
Rheumacin LA
S00108
S1723_Selleck
Sadoreum
SMR000058195
SMR000449290
SPBio_000979
SPBio_002363
Spectrum_000919
SPECTRUM1500350
Spectrum2_000970
Spectrum3_000468
Spectrum4_000018
Spectrum5_000868
Tannex
Tocris-1708
UNII-XXE1CET956
UPCMLD-DP023
UPCMLD-DP023:001
USAN
Vonum
|
|
35 |
|
Gemcitabine |
Approved |
Phase 1, Phase 2 |
|
95058-81-4 |
60750 |
Synonyms:
103882-84-4
122111-03-9
2',2'-DFDC
2',2'-DiF-dC
2',2'-difluoro-2'-Deoxycytidine
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-Hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFdC
DFDC
DFdCyd
Folfugem
Gamcitabine
Gemcel
Gemcin
Gemcitabin
|
Gemcitabina
Gemcitabina [INN-Spanish]
gemcitabine
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
GemLip
Gemtro
Gemzar
Gemzar (hydrochloride)
GEO
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY188011
LY-188011
NCGC00168784-01
NChemBio.2007.10-comp25
nchembio.573-comp7
nchembio.90-comp2
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
Zefei
ZINC18279854
|
|
36 |
|
Parathyroid hormone |
Approved, Investigational |
Phase 2 |
|
9002-64-6 |
|
Synonyms:
Parathormone
Parathormone (human recombinant)
Parathyrin
Parathyroid hormone
Parathyroid hormone (1-84) human recombinant
Parathyroid hormone (rDNA)
|
PTH
PTH(1-84)
rhPTH
rhPTH(1-84)
rPTH
rPTH(1-84)
|
|
37 |
|
Indinavir |
Approved |
Phase 2 |
|
150378-17-9 |
5362440 |
Synonyms:
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide
(2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
150378-17-9
157810-81-6
157810-81-6 (sulfate (1:1) (salt))
166746-42-5
1c6y
1hsg
1hsh
1k6c
1sdt
1sdu
1sdv
1sgu
216884-06-9
2avo
2avs
2avv
2bpx
AC1L1U7I
AC-20034
AKOS000280989
BIDD:GT0378
BIDD:PXR0141
C07051
C36H47N5O4
CHEBI:44032
Compound J
|
Crixivan
Crixivan (TM)
DB00224
IDV
indinavir
Indinavir
Indinavir (*1:1 Sulfate salt*)
Indinavir [USAN]
Indinavir anhydrous
Indinavir sulfate
Indinavir sulphate
Indinavir, sulfate (1:1)
Indinavir, Sulfate (1:1)
L 735524
L-735 524
L-735,524
L-735524
LS-173382
MK-639
MolPort-000-883-804
N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE
NCGC00159460-02
NSC697197
Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide
Propolis+Indinavir
RS-253
Sulfate, indinavir
UNII-9MG78X43ZT
|
|
38 |
|
Ritonavir |
Approved, Investigational |
Phase 2 |
|
155213-67-5 |
392622 |
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
538, ABT
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
A-84538
Abbott 84538
ABBOTT-84538
ABT 538
ABT 84538
ABT538
ABT-538
AC1L94GB
AC-733
AKOS000280930
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
DB00503
|
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
NSC693184
RIT
ritonavir
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
RTV
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
|
|
39 |
|
Zinc |
Approved, Investigational |
Phase 2 |
|
7440-66-6 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
|
Mannosidase b, alpha
Neutral alpha mannosidase
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
40 |
|
Amifostine |
Approved, Investigational |
Phase 2 |
|
20537-88-6 |
2141 |
Synonyms:
Alza brand OF amifostine
Amifostina
Amifostine
Amifostine alza brand
Amifostine anhydrous
Amifostine disodium salt
Amifostine essex brand
Amifostine ethiofos
Amifostine lilly brand
Amifostine monohydrate
Amifostine monohydrochloride
Amifostine schering-plough brand
Amifostine trihydrate
Amifostinum
Aminopropyl aminoethylthiophosphate
Aminopropylaminoethyl thiophosphate
Aminopropylaminoethylthiophosphate
Aminopropylaminoethylthiophosphoric acid
Anhydrous, amifostine
|
Anhydrous, ethiofos
Apaetp
Disodium salt, amifostine
Essex brand OF amifostine
Ethiofos
Ethiofos anhydrous
Ethyol
Gammaphos
Lilly brand OF amifostine
Monohydrate, amifostine
Monohydrochloride, amifostine
S-(N-(3-Aminopropyl)-2-aminoethyl)thiophosphoric acid
SAPEP
Schering plough brand OF amifostine
Schering-plough brand OF amifostine
Trihydrate, amifostine
US bioscience brand OF amifostine
WR-1065
|
|
41 |
|
Docetaxel |
Approved, Investigational |
Phase 2 |
|
114977-28-5 |
148124 |
Synonyms:
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
01885_FLUKA
114977-28-5
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC1L3WHJ
AC-383
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
docetaxel
Docetaxel
Docetaxel (INN)
docetaxel 114977-28-5
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxel, Trihydrate
Docetaxol
|
EmDOC
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
Taxoltere metro
Taxotere
Taxotere (TN)
Taxotere(R)
TXL
XRP-6976L
|
|
42 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-epi-Paclitaxel
7-Epipaclitaxel
7-Epi-paclitaxel
7-epi-Taxol
7-Epitaxol
7-Epi-taxol
AB00513812
ABI 007
abi-007
ABI007
ABI-007
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
AC1L1IOG
AC1L1VJI
AC1L9AVF
AC-675
ACon1_002231
albumin-bound paclitaxel
Ambotz33069-62-4
ANX-513
Anzatax
Asotax
BIDD:PXR0046
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
Bris taxol
Bristaxol
BSPBio_000290
BSPBio_001152
BSPBio_002614
C07394
C466458
C47H51NO14
Capxol
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
cMAP_000068
CPD-8718
D00491
DB01229
DHP-107
DHP-208
DivK1c_000441
DRG-0190
DTS-301
Ebetaxel
EmPAC
Epitaxol
EU-0101201
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
|
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LipoPac
LMPR0104390001
Lopac0_001201
LS-31070
MBT 0206
MEGxp0_001940
Micellar Paclitaxel
Mitotax
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
MPI-5018
nab-paclitaxel
Nanotaxel
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
NCI60_000601
Neuro_000060
NINDS_000441
NK 105
Nova-12005
NP-010981
NSC 125973
NSC125973
NSC-125973
NSC358882
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
paclitaxel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S1150_Selleck
S-8184 Paclitaxel Injectable Emulsion
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
Spectrum_001536
SPECTRUM1503908
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
ST50306996
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TaxAlbin
Taxol
TAXOL
TAXOL (TN)
Taxol a
Taxol A
Taxol Konzentrat
TAXOL, 10-EPI,
Taxol, bris
Taxol.RTM. (Registered Trademark)
TXL
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
weekly paclitaxel
Xorane
Yewtaxan
|
|
43 |
|
Hydroxyurea |
Approved |
Phase 2 |
|
127-07-1 |
3657 |
Synonyms:
127-07-1
1-HYDROXYUREA
4-03-00-00170 (Beilstein Handbook Reference)
55291_FLUKA
AC1L1GF8
AC1Q4ZXK
AI3-51139
BB_SC-7256
Bio1_000451
Bio1_000940
Bio1_001429
Biosupressin
BRN 1741548
BSPBio_002164
C07044
carbamide oxide
Carbamohydroxamate
Carbamohydroxamic acid
Carbamohydroxamic Acid
Carbamohydroximate
Carbamohydroximic acid
Carbamohydroximic Acid
Carbamohydroxyamic acid
Carbamohydroxyamic Acid
Carbamoyl oxime
Carbamoyl Oxime
Carbamyl hydroxamate
Carbamyl Hydroxamate
Carbamyl hydroxamic acid
Carrbamoyl Oxime
CCRIS 958
CHEBI:44423
CHEMBL467
CID3657
D00341
D006918
DB01005
DivK1c_000556
DRG-0253
Droxia
Droxia (TM)
Droxia (TN)
E0723DBA-5AF3-49D1-B5F6-59420AB87AC9
EINECS 204-821-7
EU-0100596
FT-0083575
H 8627
H0310
H20210
H8627_SIGMA
Hidrix
Hidroxicarbamida
Hidroxicarbamida [INN-Spanish]
HMS1920F09
HMS2091L17
HMS501L18
HSDB 6887
HU
Hydrea
Hydrea (TM)
HYDREA (TN)
Hydrea, Biosupressin, Cytodrox, Hydroxyurea
Hydreia
Hydroxicarbamidum
hydroxyaminomethanamide
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamide (JAN/INN)
Hydroxycarbamidum
Hydroxycarbamidum [INN-Latin]
Hydroxycarbamine
Hydroxyharnstoff
Hydroxyharnstoff [German]
Hydroxylurea
hydroxyurea
Hydroxyurea
HYDROXY-UREA
Hydroxyurea (D4)
|
Hydroxyurea (USP)
Hydroxyurea [USAN:BAN]
Hydroxyurea(d4)
Hydura
Hydurea
I05-0250
IDI1_000556
Idrossicarbamide
Idrossicarbamide [Dcit]
Idrossicarbamide [DCIT]
KBio1_000556
KBio2_001389
KBio2_003957
KBio2_006525
KBio3_001384
KBioGR_000383
KBioSS_001389
Litaler
Litalir
Lopac0_000596
Lopac-H-8627
LS-709
MLS001332381
MLS001332382
MLS002153389
MolMap_000029
MolPort-000-003-971
Mylocel
N-(Aminocarbonyl) Hydroxyamine
N-Carbamoylhydroxylamine
NCGC00015520-01
NCGC00015520-02
NCGC00015520-07
NCGC00093974-01
NCGC00093974-02
NCGC00093974-03
NCGC00093974-04
NCGC00093974-05
nchembio.573-comp3
nchembio.90-comp4
nchembio749-comp3
NCI C04831
NCI60_002773
NCI-C04831
NCIMech_000139
NHY
N-HYDROXY UREA
N-Hydroxymocovina
N-Hydroxymocovina [Czech]
N-Hydroxyurea
N-HYDROXYUREA
NINDS_000556
NSC 32065
NSC32065
Oncocarbide
Onco-carbide
Onco-Carbide
Oxyurea
S1896_Selleck
Siklos
SK 22591
SMR000059149
SPBio_000247
Spectrum_000909
SPECTRUM1500344
Spectrum2_000064
Spectrum3_000462
Spectrum4_000012
Spectrum5_000836
S-phase/G-1 interface inhibitor
SQ 1089
SQ-1089
Sterile Urea
tetratogen: inhibits ribonucleoside diphosphate reductase
TL8000673
UNII-X6Q56QN5QC
Ureaphil
WLN: ZVMQ
|
|
44 |
|
Zinc oxide |
Approved |
Phase 2 |
|
1314-13-2 |
|
Synonyms:
óxido de cinc
oxyde de zinc
Zinc (as oxide)
Zinc (as zinc oxide)
Zinc óxido
|
Zinc white
Zinci oxydum
Zincum oxydatum
Zinkoxid
|
|
45 |
|
Valproic acid |
Approved, Investigational |
Phase 2 |
|
99-66-1 |
3121 |
Synonyms:
(N-C3H7)2chcooh
(S)-2-Propyl-4-pentanoate
(S)-2-Propyl-4-pentanoic acid
2 PP (base)
2 Propylpentanoic acid
2-N-Propyl-N-valerate
2-n-propyl-n-valeric acid
2-n-Propyl-n-valeric acid
2-N-Propyl-N-valeric acid
2-Propylpentanoate
2-PROPYL-pentanoate
2-propyl-pentanoic acid
2-Propylpentanoic acid
2-Propylpentanoic Acid
2-PROPYL-pentanoIC ACID
2-Propylvalerate
2-propylvaleric acid
2-Propylvaleric acid
2-Propylvaleric Acid
4-Heptanecarboxylate
4-heptanecarboxylic acid
4-Heptanecarboxylic acid
76584-70-8 (hydrochloride salt (2:1))
99-66-1
Abbott 44090
AC1L1F7T
AC1Q2ULA
Acetate, dipropyl
Acid, propylisopropylacetic
Acid, valproic
Acide valproique
acide valproïque
Acide valproique [INN-French]
acido Valproico
Acido valproico
ácido valproico
Acido valproico [INN-Spanish]
acidum valproicum
Acidum valproicum
Acidum valproicum [INN-Latin]
AI3-10500
Alti-valproic
Alti-Valproic
apo-Divalproex
apo-Valproic
apo-Valproic syrup
Avugane
Baceca
BIDD:GT0858
BRN 1750447
C07185
Calcium valproate
Calcium, valproate
CHEBI:39867
CHEMBL109
CID3121
Convulex
Convulsofin
CPD000499581
D00399
DB00313
Delepsine
Depacon
Depakene
Depakene (TN)
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Depakote (TM)
Deproic
Di-N-propylacetate
di-n-propylacetic acid
Di-n-propylacetic acid
Di-N-propylacetic acid
Di-n-propylessigsaeure
Di-N-propylessigsaeure
Di-n-propylessigsaure
Di-N-propylessigsaure
Di-n-propylessigsäure
Di-n-propylessigsaure [German]
Dipropyl acetate
Dipropyl Acetate
Dipropylacetate
Dipropylacetic acid
Divalproex
Divalproex sodium
DivK1c_000273
DOM-divalproex
Dom-valproate
Dom-Valproic
DOM-valproic
Dom-valproic acid
DOM-valproic acid e.c.
Dom-valproic acid syrup
DPA
EINECS 202-777-3
Epiject i.v.
Epilex
Epilim
Epival
Epival er
Ergenyl
G2M-777
Gen-divalproex
HMS2089J06
HSDB 3582
I04-0211
InChI=1/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
KBio1_000273
KBio2_001001
KBio2_002277
KBio2_003569
|
KBio2_004845
KBio2_006137
KBio2_007413
KBio3_002626
KBio3_002757
KBioGR_000871
KBioGR_002277
KBioSS_001001
KBioSS_002278
Kyselina 2-propylvalerova
Kyselina 2-propylvalerova [Czech]
LS-161170
LS-2068
Magnesium valproate
Med valproic
Med Valproic
MLS001076682
MLS001335927
MLS001335928
MLS002415770
MolPort-001-791-895
Mylproin
Myproate
Myproic acid
Myproic Acid
NCGC00091149-01
NCGC00091149-02
NCGC00091149-03
NCGC00091149-04
nchembio.79-comp4
nchembio815-comp21
n-Dipropylacetic acid
N-Dipropylacetic acid
n-DPA
N-DPA
NINDS_000273
novo-Divalproex
novo-Valproic
Novo-Valproic
novo-Valproic - ecc
novo-Valproic soft gel cap
NSC 93819
NSC93819
Nu-valproic
Nu-Valproic
P0823
P6273_SIGMA
PEAC
Penta-valproic
Penta-Valproic
PHL-Valproate
PHL-Valproic acid
PHL-Valproic acid e.c.
PMS-Divalproex
PMS-Valproate
PMS-Valproic acid
PMS-Valproic Acid
PMS-Valproic acid e.c.
Propylisopropylacetic acid
Propylvaleric acid
ratio-Valproic - ecc
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
SAM002564230
Sandoz valproic
Savicol
SBB065764
Semisodium valproate
Semisodium Valproate
SMR000499581
Sodium hydrogen divalproate
Sodium valproate
Sodium, divalproex
Sodium, valproate
SPBio_000912
Spectrum_000521
Spectrum2_000946
Spectrum3_001733
Spectrum4_000376
Sprinkle
Stavzor
UNII-614OI1Z5WI
Valcote
Valparin
valproate
Valproate
Valproate calcium
Valproate semisodique [French]
Valproate semisodium
Valproate sodium
Valproate, calcium
Valproate, magnesium
Valproate, semisodium
Valproate, sodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
valproic acid
Valproic acid
VALPROIC ACID
Valproic acid (USP)
Valproic acid [USAN:INN:BAN]
Valproic acid usp
Valproic acid USP
Valproic acid USP24
Valproic acid, sodium salt (2:1)
Valproic Acid, Sodium Salt (2:1)
Valproinsaeure
Valproinsäure
VPA
Vupral
WLN: QVY3 & 3
|
|
46 |
|
Cetuximab |
Approved |
Phase 2 |
|
205923-56-4 |
56842117 2333 |
Synonyms:
205923-56-4
Anti EGFR
cetuximab
Cetuximab
Cétuximab
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
|
Cetuximab (USAN/INN)
Cetuximabum
D03455
Erbitux
Erbitux (TN)
IMC-C225
|
|
47 |
|
Tegafur |
Approved, Investigational |
Phase 2 |
|
17902-23-7 |
5386 |
Synonyms:
1-(2-Tetrahydrofuryl)-5-fluorouracil
|
|
|
48 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
|
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
49 |
|
Sargramostim |
Approved, Investigational |
Phase 2 |
|
83869-56-1, 123774-72-1 |
|
Synonyms:
123774-72-1
D05803
Leukine
Leukine (TN)
Recombinant human granulocyte-macrophage colony stimulating factor
rGM-CSF
|
rHu GM-CSF
Sargramostim
Sargramostim (genetical recombination)
Sargramostim (genetical recombination) (JAN)
Sargramostim (USAN/INN)
|
|
50 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
|
Synonyms:
|
Interventional clinical trials:
(show top 50)
(show all 107)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Comparing the Lozenge to the Patch for Smoking Cessation |
Completed |
NCT00365508 |
Phase 4 |
nicotine lozenge;nicotine patch |
2 |
Enhancing Tobacco Use Treatment for African American Light Smokers |
Completed |
NCT00666978 |
Phase 4 |
bupropion hydrochloride |
3 |
A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy |
Unknown status |
NCT00022373 |
Phase 3 |
iseganan HCl oral solution |
4 |
A Phase III Study to Test the Efficacy and Safety of GM-CSF to Reduce the Severity and Duration of Mucosal Injury and Pain (Mucositis) Associated With Curative Radiation Therapy in Head and Neck Cancer Patients |
Completed |
NCT00008398 |
Phase 3 |
|
5 |
Phase III Placebo-Controlled Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Patients |
Completed |
NCT00201279 |
Phase 3 |
13-cis Retino Acid |
6 |
Phase III Study Of Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients |
Completed |
NCT00201383 |
Phase 3 |
cisplatin |
7 |
A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia |
Completed |
NCT00656513 |
Phase 2, Phase 3 |
Pilocarpine |
8 |
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer |
Not yet recruiting |
NCT04333537 |
Phase 2, Phase 3 |
Imaging Agent |
9 |
Multicentre,A Phase II/III Randomized Study of Adjuvant Anti-Angiogenesis Therapy for Patients of High-Risk Oral Cavity Cancer |
Terminated |
NCT00934739 |
Phase 2, Phase 3 |
Thalidomide, Celebrex;Cyclophosphamide, Dexamethasone |
10 |
Randomized Phase III Trial on Postoperative Chemoradiation in Combination With Anti EGFR-Antibody Versus Postoperative Chemoradiation in Head and Neck Squamous Cell Carcinomas (HNSCC) With High Risk of Locoregional Recurrence |
Withdrawn |
NCT01142414 |
Phase 3 |
cisplatin;fluorouracil |
11 |
A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity |
Unknown status |
NCT02609386 |
Phase 2 |
Cyclophosphamide;Indomethacin;Omeprazole |
12 |
Phrase II Single Arm Study of Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral |
Unknown status |
NCT03008694 |
Phase 2 |
|
13 |
A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Previously Treated Patients With Advanced Head and Neck Cancer |
Unknown status |
NCT00003327 |
Phase 2 |
paclitaxel |
14 |
A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer |
Unknown status |
NCT00003251 |
Phase 1, Phase 2 |
amifostine trihydrate;cisplatin;paclitaxel |
15 |
A Phase I/II Study Using Cisplatin and Gemcitabine (Gemzar) for Advanced Head and Neck Cancer (Squamous Cell Carcinoma) |
Unknown status |
NCT00003182 |
Phase 1, Phase 2 |
cisplatin;gemcitabine hydrochloride |
16 |
CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment Followed by 6 Weeks of Cetuximab+RT Post Surgery in Locally Advanced Squamous Cell Carcinoma of the Tongue ; A NEW PARADIGM OF TREATMENT |
Unknown status |
NCT01760811 |
Phase 1, Phase 2 |
Erbitux,merck serono |
17 |
Health and Economic Outcomes of Two Different Follow up Strategies in Effectively Cured Advanced Head and Neck Cancer |
Unknown status |
NCT02262221 |
Phase 2 |
|
18 |
Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study |
Unknown status |
NCT00637637 |
Phase 2 |
indinavir sulfate;ritonavir |
19 |
A Preoperative Window of Opportunity Study to Assess the Modulation of Biomarkers in the Primary Tumor Site of Patients With Resectable Oral Cavity Cancer (OCC) Randomized to Receive Preoperative Treatment With PF-00299804 |
Completed |
NCT01116843 |
Phase 1, Phase 2 |
PF-00299804 |
20 |
Pilot Study for the Diagnosis of Head and Neck Cancer: Photofrin and Visible Light |
Completed |
NCT00002964 |
Phase 2 |
porfimer sodium |
21 |
Efficacy of Implant-Supported Maxillofacial Prostheses |
Completed |
NCT00006341 |
Phase 2 |
|
22 |
A Pilot Study of Combined Modality Therapy for Recurrent Head and Neck Carcinoma |
Completed |
NCT00003777 |
Phase 2 |
amifostine trihydrate;cisplatin;fluorouracil |
23 |
Phase II Study of Preoperative TPF Chemotherapy in Locally Advanced Resectable Oral Cavity Squamous Cell Cancer in Order to Improve the Rate of Pathological Complete Response |
Completed |
NCT01914900 |
Phase 2 |
docetaxel, cisplatin, 5 fluorouracil |
24 |
Hyperfractionated Radiotherapy With Concomitant Fluorouracil and Hydroxurea for Intermediate Stage Cancer of the Head and Neck |
Completed |
NCT00002951 |
Phase 2 |
fluorouracil;hydroxyurea |
25 |
Phase II Double-Blind, Placebo Controlled, Randomized Study Of Celecoxib, A Selective COX-2 Inhibitor, In Oral Premalignant Lesions |
Completed |
NCT00014404 |
Phase 2 |
celecoxib |
26 |
Efficacy Evaluation of the Combination of Valproic Acid and Standard Platinum-based Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma |
Completed |
NCT01695122 |
Phase 2 |
Valproic Acid |
27 |
A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging |
Completed |
NCT00565721 |
Phase 2 |
Fluciclatide Injection - (AH111585 (F18)) |
28 |
Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers? |
Completed |
NCT00376987 |
Phase 2 |
|
29 |
A Phase IIb Cancer Prevention Trial of Celecoxib, a Selective COX-2 Inhibitor, in Oral Leukoplakia |
Completed |
NCT00101335 |
Phase 2 |
celecoxib |
30 |
A Randomized, Double Blind, Placebo-Controlled Phase II Clinical Trial of N(4-Hydroxy-phenyl)Retinamide (Fenretinide, 4HPR) in Oral Leukoplakia |
Completed |
NCT00004161 |
Phase 2 |
fenretinide;Placebo |
31 |
Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study |
Completed |
NCT00052611 |
Phase 2 |
Celecoxib |
32 |
Physiotherapy Versus no Physiotherapy to Patients Suffering From Head and Neck Cancer Undergoing Radiotherapy Treatment |
Completed |
NCT00780312 |
Phase 2 |
|
33 |
A Phase II Multi-Center Study of Concomitant Cetuximab and Cisplatin With Re-Irradiation Using Intensity-Modulated Radiotherapy in Patients With Recurrent Squamous Cell Carcinoma of the Head-and-Neck |
Completed |
NCT00833261 |
Phase 2 |
cetuximab;cisplatin;Nab-Paclitaxel |
34 |
Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions |
Completed |
NCT00524017 |
Phase 2 |
|
35 |
Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial |
Completed |
NCT00330382 |
Phase 2 |
Bowman-Birk inhibitor concentrate |
36 |
Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135] |
Completed |
NCT00064103 |
Phase 1, Phase 2 |
|
37 |
A Phase II Study of the Effects of Extended Pre-Cessation Bupropion for Smoking Cessation |
Completed |
NCT00534001 |
Phase 2 |
bupropion hydrochloride |
38 |
Phase II Trial of Nivolumab, an Anti-PD-1 Monoclonal Antibody, as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer |
Recruiting |
NCT03021993 |
Phase 2 |
Nivolumab |
39 |
Patient-reported Outcome After Radiotherapy of Oral Cavity and Sinonasal Cancer Using an Intraoral Stent |
Recruiting |
NCT04330781 |
Phase 2 |
|
40 |
A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
Recruiting |
NCT03422536 |
Phase 2 |
Ficlatuzumab |
41 |
A Phase II Study of Maintenance Tegafur-uracil in Patients With Squamous Cell Carcinoma of Oral Cavity With Extracapsular Spreading of Lymph Nodes |
Recruiting |
NCT03121313 |
Phase 2 |
tegafur-uracil |
42 |
The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab With Valproic Acid for the Treatment of Virus-associated Cancer |
Recruiting |
NCT03357757 |
Phase 2 |
Valproic Acid |
43 |
Phase II Non-Randomised Controlled Trial Of Concomitant Immune Check Point Inhibitor With Radiotherapy And Chemotherapy Or Cetuximab In Advanced Non Metastatic Head And Neck Cancer |
Recruiting |
NCT03532737 |
Phase 2 |
Pembrolizumab |
44 |
A Randomized Multicenter Phase II Study Using (2-1[Heyloxyethyl]-2-Devinylpyropheophorbide-a) (HPPH) With PDT Versus Standard of Care Surgery for Patients With T1/T2 N0 Squamous Cell Carcinoma of the Oral Cavity |
Active, not recruiting |
NCT03090412 |
Phase 2 |
HPPH;Photodynamic Therapy |
45 |
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients With High-Risk Squamous Cell Carcinoma of the Oral Cavity |
Active, not recruiting |
NCT02873819 |
Phase 2 |
GL-0817;Hiltonol;Sargramostim;cyclophosphamide;Placebo |
46 |
Personalized, Randomized, Phase 2 Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias |
Active, not recruiting |
NCT02882282 |
Phase 2 |
|
47 |
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity |
Active, not recruiting |
NCT02919683 |
Phase 2 |
Nivolumab;Ipilimumab |
48 |
A Phase II Open-label, Single Arm Study to Evaluate the Efficacy of Sintilimab(IBI 308) to Prevent High-risk Oral Premalignant Lesions Cancerization |
Not yet recruiting |
NCT04065737 |
Phase 2 |
Sintilimab |
49 |
NICO - CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer |
Not yet recruiting |
NCT03721757 |
Phase 2 |
|
50 |
Open Label Single Arm Phase Ib-II Study of Pre-operative IPH2201 in Patients With Locally Advanced Resectable Squamous Cell Carcinoma of the Oral Cavity |
Terminated |
NCT02331875 |
Phase 1, Phase 2 |
IPH2201 |
|